Key facts
- This page summarizes Gil Efron's Form 3 filing for PURPLE BIOTECH LTD. (PPBT).
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 31 Mar 2026, 07:48.
Gil Efron - 18 Mar 2026 Form 3 Insider Report for PURPLE BIOTECH LTD. (PPBT)
- Reporting relationship
- Chief Executive Officer
- Issuer ticker
- PPBT
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Gil Efron
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Gil Efron filed Form 3 for PURPLE BIOTECH LTD. (PPBT) on 31 Mar 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002124517
Primary reporting owner
Efron Gil
- Relationship
- Chief Executive Officer
- Address
- 4 OPPENHEIMER STREET, SCIENCE PARK, REHOVOT, ISRAEL
- Signature
- /s/ Gil Efron
- Signature date
- 31 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PPBT
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 15,750,000
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PPBT
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 1,500,000
- Exercise price
- Footnotes
- F2
PPBT
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 3,750,000
- Exercise price
- Footnotes
- F3
PPBT
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 13,500,000
- Exercise price
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Includes 12,375,000 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.
Footnote F2
Represents stock option to purchase 1,500,000 Ordinary Shares (equivalent to 750 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The Ordinary Shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.095054688 per Ordinary Share and the option expires on May 23, 2027.
Footnote F3
Represents stock option to purchase 3,750,000 Ordinary Shares (equivalent to 1,875 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The Ordinary Shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.0765625 per Ordinary Share and the option expires on July 11, 2027.
Footnote F4
Represents stock option to purchase 13,500,000 Ordinary Shares (equivalent to 6,750 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 1,125,000 Ordinary Shares are vested and exercisable, with the remaining options to purchase 12,375,000 Ordinary Shares vesting in equal quarterly installments until October 21, 2028. The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030.